Gilead Sciences rose 40.9% in a year. Moderna rose 9.3-fold.

Same industry

GILD against four biotech peers, a year at 100

GILD is up 40.9% in a year. Moderna is up 9.3 times, Exelixis is up 77.2%, Biogen 60.1% and Amgen 44.1%. All four did more. Weekly closes, Nov 7, 2025 = 100, on a log scale so a 9.3-fold rise and a 40.9% rise both read honestly.

Share this chart

GILD +40.9%. Moderna ×9.3, Exelixis +77.2%, Biogen +60.1%, Amgen +44.1%. Weekly closes, Nov 7, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in GILD’s SEC industry (Biological Products, (No Diagnostic Substances)) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

GILD: stories, the record and filings →